EUVIMEDEUVIMED entdecken
Crossref

Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy

Kyuwan Lee, Aleksi Iukuridze, Tianhui He, Alysia Bosworth, Lanie Lindenfeld, Jennifer Berano Teh, Meagan Echevarria, Sophia Albanese, Liezl Atencio, Rusha Bhandari, F Lennie Wong, Andrew S Artz und 10 weitere

Journal of the National Comprehensive Cancer Network · 2023

DOI: 10.6004/jnccn.2022.7100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2023. Verfasst von Kyuwan Lee und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Neurotoxicity Syndromes. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The purpose of this study was to examine the association between baseline skeletal muscle measurements, acute toxicity (immune effector cell–associated neurotoxicity syndrome [ICANS], cytokine release syndrome), and treatment efficacy in patients undergoing CAR T-cell therapy for B-lineage lymphoma. Patients and Methods: Skeletal muscle measurements were obtained from automated CT measurements in 226 consecutive patients who received CAR T-cell therapy between 2015 and 2021. The Kaplan-Meier method was used to examine progression-free survival (PFS) and overall survival (OS) at 1-year. Multivariable regression was used to calculate the hazard ratio (HR) with 95% confidence intervals, adjusted for covariates.

Results

The median age of the cohort was 63.1 years (range, 18.5–82.4 years), and most patients were male (66%) and had primary refractory disease (58%). Patients with abnormally low skeletal muscle at baseline were at greater risk of ICANS (HR, 1.74; 95% CI, 1.05–2.87) and had longer length of hospitalization (mean 27.7 vs 22.9 days; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveNeurotoxicity SyndromesHumansMaleAdolescentYoung AdultAdultMiddle AgedAgedAged, 80 and overFemaleDisease ProgressionMuscle, Skeletal

Stichwörter der Autor:innen

Lymphomachimeric antigen receptor T-cell therapyoutcomessurvivaltoxicity

Substanzen

cell-associated neurotoxicity

Autor:innen und Institutionen

  • Department of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California.
  • Department of Pediatrics, City of Hope Comprehensive Cancer Center, Duarte, California.
  • Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California.

Zitieren

APA

Lee, K., Iukuridze, A., He, T., Bosworth, A., Lindenfeld, L., Teh, J. B., Echevarria, M., Albanese, S., Atencio, L., Bhandari, R., Wong, F. L., Artz, A. S., Siddiqi, T., Nikolaenko, L., Zain, J., Mei, M., Shouse, G., Popplewell, L. L., Herrera, A. F., …, & Armenian, S. H. (2023). Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2022.7100

Vancouver

Lee K, Iukuridze A, He T, Bosworth A, Lindenfeld L, Teh JB, et al. Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy. Journal of the National Comprehensive Cancer Network. 2023. doi:10.6004/jnccn.2022.7100

BibTeX
@article{Lee2023,
  author = {Lee, Kyuwan and Iukuridze, Aleksi and He, Tianhui and Bosworth, Alysia and Lindenfeld, Lanie and Teh, Jennifer Berano and Echevarria, Meagan and Albanese, Sophia and Atencio, Liezl and Bhandari, Rusha and Wong, F Lennie and Artz, Andrew S and Siddiqi, Tanya and Nikolaenko, Liana and Zain, Jasmine and Mei, Matthew and Shouse, Geoffrey and Popplewell, Leslie L and Herrera, Alex F and Budde, L Elizabeth and Forman, Stephen J and Armenian, Saro H},
  title = {Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2023},
  doi = {10.6004/jnccn.2022.7100}
}
Kostenlos starten →